| 2010 | |
June 7, 2010 |
|
 |
Cytheris Closes €12 Million ($15 Million) Series D Financing |
 |
|
March 16, 2010 |
|
|
Cytheris Announces Publication of Preclinical Study in Journal of Immunology Showing Interleukin-7 Promotes T Cell Viability, Trafficking, and Functionality While Improving Survival in Sepsis |
|
|
February 2, 2010 |
|
|
Cytheris Announces Notice of Allowance for U.S. Patent Covering the Preparation and Uses of its Glycosylated Recombinant Human Interleukin-7 (CYT107) |
|
|
January 12, 2010 |
|
|
Cytheris Initiates INSPIRE 2, a Phase II Clinical Trial of Recombinant Human Interleukin-7 (CYT107) in Chronically Infected HIV Patients Who Fail to Achieve Optimal Immune Reconstitution under HAART Therapy |
|
|
Cytheris SA, a privately held clinical-stage biopharmaceutical company with headquarters in a suburb of Paris, France, is focused on research and development of new therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT).
The company’s lead compound, recombinant human Interleukin-7 (r-hIL-7), is a critical growth factor for immune T cell recovery and enhancement. Cytheris is currently conducting multiple international clinical studies of IL-7 in HIV, HBV, HCV and cancer.